Pharmacology of traumatic brain injury: Where is the "golden bullet"?

Molecular Medicine

Volumn 14, Issue 11-12, 2008, Pages 731-740

  Beauchamp, Kathryn ^a   Mutlak, Haitham ^b,c   Smith, Wade R ^a   Shohami, Esther ^d   Stahel, Philip F ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF COLORADO   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ANANDAMIDE; ANATIBANT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; CORTICOSTEROID; CYCLOSPORIN; D CCP ENE; DELBITANT; DELTIBANT; DEXANABINOL; EAA 494; GCS 19755; GLUTAMIC ACID; KALLIKREIN; KININ; LF 16 0687MA; MAGNESIUM SULFATE; METABOTROPIC RECEPTOR; METHYLPHENIDATE; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NIMODIPINE; NOLADIN ETHER; PLACEBO; PROGESTERONE; TIRILAZAD; TRAXOPRODIL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPOTENSION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ADRENAL CORTEX HORMONES; ANIMALS; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; HUMANS; MODELS, BIOLOGICAL; PIPECOLIC ACIDS; PROGESTERONE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 55749111251     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2008-00050.Beauchamp     Document Type: Review

References (129)

1. Myburgh et al. (2008) Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J. Trauma 64:854-62.
2. Koskinen S, Alaranta H. (2008) Traumatic brain injury in Finland 1991-2005: A nationwide register study of hospitalized and fatal TBI. Brain Inj. 22:205-14.
3. Wrona RM. (2006) The use of state workers' compensation administrative data to identify injury scenarios and quantify costs of work-related traumatic brain injuries. J. Safety Res. 37:75-81.
4. Davis KL, Joshi AV, Tortella BJ, Candrilli SD. (2007) The direct economic burden of blunt and penetrating trauma in a managed care population. J. Trauma 62:622-629.
5. Gamboa AMJ, Holland GH, Tierney JP, Gibson DS. (2006) American Community Survey: earnings and employment for persons with traumatic brain injury. NeuroRehabilitation 21:327-33.
6. Woolhandler S, Himmelstein DU. (2006) Double catastrophe: injury-related bankruptcies. Med. Care 45:699-701.
7. Stahel PF, Smith WR, Moore EE. (2008) Hypoxia and hypotension, the "lethal duo" in traumatic brain injury: implications for prehospital care. Intensive Care Med. 34:402-4.
8. The Brain Trauma Foundation. (2007) Guidelines for the management of severe traumatic brain injury. J. Neurotrauma 24: S1-6.
9. Ghallich JH FL. (1961) The use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am. Pract. Dig. Treat. 12:169-74.
10. Gobiet W. (1982) Osmotherapy and steroid therapy in acute brain edema [in German]. Schweiz Med. Wochenschr. 112:966-967.
11. Roberts I et al. (2004) Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 364:1321-8.
12. Sauerland S, Maegele M. (2004) A CRASH landing in severe head injury. Lancet 364:1291-2.
13. The Brain Trauma Foundation. (2007) Guidelines for the management of severe traumatic brain injury; XV: steroids. J. Neurotrauma 24:S91-5.
14. Hall ED, Yonkers PA, McCall JM, Braughler JM. (1988) Effects of the 21-aminosteroid U74006F on experimental head injury in mice. J. Neurosurg. 68:456-61.
15. Braughler JM, Pregenzer JF. (1989) The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals. Free Radic. Biol. Med. 7:125-30.
16. Clark WM, Hazel JS, Coull BM. (1995) Lazaroids: CNS pharmacology and current research. Drugs 50:971-83.
17. Hall ED, Braughler JM. (1989) Central nervous system trauma and stroke; II: physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic. Biol. Med. 6:303-13.
18. Hall ED, Braughler JM. (1993) Free radicals in CNS injury. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 71:81-105.
19. Hall ED, McCall JM, Means ED. (1994) Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv. Pharmacol. 28:221-68.
20. Kontos HA, Povlishock JT. (1986) Oxygen radicals in brain injury. Cent. Nerv. Syst. Trauma 3:257-263.
21. Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA, Ho NF. (1993) Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug Target. 1:269-86.
22. Marshall LF et al. (1998) A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurg. 89:519-25.
23. Roberts I. (2000) Aminosteroids for acute traumatic brain injury. Cochrane Database Syst. Rev: CD001527.
24. Behl C. (2002) Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 3:433-42.
25. Roof RL, Hoffman SW, Stein DG. (1997) Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol. Chem. Neuropathol. 31:1-11.
26. Asbury ET, Fritts ME, Horton JE, Isaac WL. (1998) Progesterone facilitates the acquisition of avoidance learning and protects against subcortical neuronal death following prefrontal cortex ablation in the rat. Behav. Brain Res. 97:99-106.
27. Pettus EH, Wright DW, Stein DG, Hoffman SW. (2005) Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Res. 1049:112-9.
28. Roof RL, Duvdevani R, Braswell L, Stein DG. (1994) Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp. Neurol. 129:64-9.
29. Roof RL, Duvdevani R, Heyburn JW, Stein DG. (1996) Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. Exp. Neurol. 138:246-51.
30. Shear DA, Galani R, Hoffman SW, Stein DG. (2002) Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp. Neurol. 178:59-67.
31. Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. (1999) Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 24:2134-8.
32. Wright DW, Bauer ME, Hoffman SW, Stein DG. (2001) Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J. Neurotrauma 18:901-9.
33. Wright DW, Ritchie JC, Mullins RE, Kellermann AL, Denson DD. (2005) Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury. J. Clin. Pharmacol. 45:640-8.
34. Wright DW et al. (2007) ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49:391-402, 402 e391-2.
35. Xiao G, Wei J, Yan W, Wang W, Lu Z. (2008) Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 12:R61.
36. Meldrum BS. (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. 130:1007S-15S.
37. Tapiero H, Mathe G, Couvreur P, Tew KD. (2002) II. Glutamine and glutamate. Biomed. Pharmacother. 56:446-57.
38. Platt SR. (2007) The role of glutamate in central nervous system health and disease: a review. Vet. J. 173:278-86.
39. Sayin U, Rutecki PA. (2003) Group I metabotropic glutamate receptor activation produces prolonged epileptiform neuronal synchronization and alters evoked population responses in the hippocampus. Epilepsy Res. 53:186-95.
40. Birnbaumer L et al. (1994) The naming of voltage-gated calcium channels. Neuron 13:505-6.
41. Levy LM, Warr O, Attwell D. (1998) Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. J. Neurosci. 18:9620-8.
42. Yano S, Tokumitsu H, Soderling TR. (1998) Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396:584-7.
43. Bullock R et al. (1998) Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 89:507-18.
44. Palmer AM, Marion DW, Botscheller ML, Swedlow PE, Styren SD, DeKosky ST. (1993) Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J. Neurochem. 61:2015-24.
45. Yi JH, Hazell AS. (2006) Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 48:394-403.
46. Chen MH, Bullock R, Graham DI, Miller JD, McCulloch J. (1991) Ischemic neuronal damage after acute subdural hematoma in the rat: effects of pretreatment with a glutamate antagonist. J. Neurosurg. 74:944-50.
47. Menniti F, Chenard B, Collins M, Ducat M, Shalaby I, White F. (1997) CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. J. Pharmacol. 331:117-26.
48. Menniti FS, Pagnozzi MJ, Butler P, Chenard BL, Jaw-Tsai SS, Frost White W. (2000) CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology 39:1147-55.
49. Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF. (1999) Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J. Neurosurg. 91:737-43.
50. Chenard BL et al. (1995) (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy- 4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. 38:3138-45.
51. Merchant RE et al. (1999) A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. N. Y. Acad. Sci. 890:42-50.
52. Yurkewicz L, Weaver J, Bullock MR, Marshall LF. (2005) The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J. Neurotrauma 22:1428-43.
53. Narayan RK et al. (2002) Clinical trials in head injury. J. Neurotrauma 19:503-557.
54. Sanders GT, Huijgen HJ, Sanders R. (1999) Magnesium in disease: a review with special emphasis on the serum ionized magnesium. Clin. Chem. Lab. Med. 37:1011-33.
55. Dacey MJ. (2001) Hypomagnesemic disorders. Crit. Care Clin. 17:155-73, viii.
56. Kahraman S, Ozgurtas T, Kayali H, Atabey C, Kutluay T, Timurkaynak E. (2003) Monitoring of serum ionized magnesium in neurosurgical intensive care unit: preliminary results. Clin. Chim. Acta. 334:211-15.
57. Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. (2000) Hypomagnesemia and hypophosphatemia at admission in patients with severe head injury. Crit. Care Med. 28:2022-5.
58. Vink R, McIntosh TK, Demediuk P, Weiner MW, Faden AI. (1988) Decline in intracellular free Mg2+ is associated with irreversible tissue injury after brain trauma. J. Biol. Chem. 263:757-61.
59. McIntosh TK, Faden AI, Yamakami I, Vink R. (1988) Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 31P magnetic resonance spectroscopy and behavioral studies. J. Neurotrauma 5:17-31.
60. Saatman KE, Bareyre FM, Grady MS, McIntosh TK. (2001) Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J. Neuropathol. Exp. Neurol. 60:183-94.
61. Feldman Z, Gurevitch BA, Artru AA, Oppenheim A, Shohami E, Reichenthal E, Shapira Y. (1996) Magnesium given one hour following head trauma decreases brain edema and improves neurological outcome. J. Neurosurg. 85:131-7.
62. Arango MF, Mejia-Mantilla JH. (2006) Magnesium for acute traumatic brain injury. Cochrane Database Syst. Rev. CD005400.
63. Temkin NR et al. (2007) Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 6:29-38.
64. Biegon A, Fry PA, Paden CMA, Tsenter J, Shohami E. (2004) Delayed Activation, rather than inhibition, of glutamate NMDA receptors improves neurological outcome after closed head injury in mice. Proc. Natl. Acad. Sci. U. S. A. 101 5117-22.
65. Yaka R et al. (2007) D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 21:2033-41.
66. Axelrod J, Felder CC. (1998) Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem. Res. 23:575-81.
67. Elphick MR, Egertova M. (2001) The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:381-408.
68. Mechoulam R, Fride E, Di Marzo V. (1998) Endocannabinoids. Eur. J. Pharmacol. 359:1-18.
69. Pertwee RG. (1999) Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:635-64.
70. Devane WA et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-9.
71. Mechoulam R et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83-90.
72. Hanus L et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98:3662-5.
73. Schmid HH. (2000) Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids 108:71-87.
74. Fowler CJ, Jonsson KO, Tiger G. (2001) Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem. Pharmacol. 62:517-526.
75. Mechoulam R, Spatz M, Shohami E. (2002) Endocannabinoids and neuroprotection. Sci. STKE 2002:RE5.
76. Ullrich O, Merker K, Timm J, Tauber S. (2007) Immune control by endocannabinoids - new mechanisms of neuroprotection? J. Neuroimmunol. 184:127-35.
77. Feigenbaum JJ et al. (1989) Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U. S. A. 86:9584-7.
78. Mechoulam R et al. (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44:762-4.
79. Eshhar N, Striem S, Kohen R, Tirosh O, Biegon A. (1995) Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 283:19-29.
80. Gallily R et al. (1997) Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283:918-24.
81. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol. 72:169-77.
82. Chan PH. (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21:2-14.
83. Shohami E, Ginis I, Hallenbeck JM. (1999) Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 10:119-130.
84. Brewster ME et al. (1997) Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int. J. Clin. Pharmacol. Ther. 35:361-5.
85. Knoller N et al. (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30:548-54.
86. Maas AI et al. (2006) Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5:38-45.
87. Forsyth RJ, Jayamoni B, Paine TC. (2006) Monoaminergic agonists for acute traumatic brain injury. Cochrane Database Syst. Rev. CD003984.
88. Marklund N, Bakshi A, Castelbuono DJ, Conte V, McIntosh TK. (2006) Evaluation of pharmacological treatment strategies in traumatic brain injury. Curr. Pharm. Des. 12:1645-80.
89. Siddall OM. (2005) Use of methylphenidate in traumatic brain injury. Ann. Pharmacother. 39:1309-13.
90. Husson I, Mesples B, Medja F, Leroux P, Kosofsky B, Gressens P. (2004) Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties. Neuroscience 125:163-70.
91. Alban JP, Hopson MM, Ly V, Whyte J. (2004) Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Am. J. Phys. Med. Rehabil. 83:131-7; quiz 138-41, 167.
92. Burke DT et al. (2003) Effects of methylphenidate on heart rate and blood pressure among inpatients with acquired brain injury. Am. J. Phys Med. Rehabil. 82:493-7.
93. Moein H, Khalili HA, Keramatian K. (2006) Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin. Neurol. Neurosurg. 108:539-42.
94. Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock MR. (2002) Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J. Neurotrauma 19:829-41.
95. Buki A, Okonkwo DO, Povlishock JT. (1999) Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J. Neurotrauma 16:511-21.
96. Okonkwo DO, Buki A, Siman R, Povlishock JT. (1999) Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 10:353-8.
97. Okonkwo DO, Povlishock JT. (1999) An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J. Cereb. Blood Flow Metab. 19:443-451.
98. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. (2005) Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J. Neurosci. Res. 79:231-239.
99. Sullivan PG, Thompson M, Scheff SW. (2000) Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp. Neurol. 161:631-7.
100. Sullivan PG, Thompson MB, Scheff SW. (1999) Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp. Neurol. 160:226-34.
101. Kronbach T, Fischer V, Meyer UA. (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630-5.
102. Empey PE, McNamara PJ, Young B, Rosbolt MB, Hatton J. (2006) Cyclosporin A disposition following acute traumatic brain injury. J. Neurotrauma 23:109-16.
103. Ercan M, Inci S, Kilinc K, Palaoglu S, Aypar U. (2001) Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats. Neurosurg. Rev. 24:127-30.
104. Nilsson P, Hillered L, Olsson Y, Sheardown MJ, Hansen AJ. (1993) Regional changes in interstitial K+ and Ca2+ levels following cortical compression contusion trauma in rats. J. Cereb. Blood Flow Metab. 13:183-92.
105. Shapira Y, Yadid G, Cotev S, Shohami E. (1989) Accumulation of calcium in the brain following head trauma. Neurol Res. 11:169-72.
106. The European Study Group on Nimodipine in Severe Head Injury (1994) A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J. Neurosurg. 80:797-804.
107. Bailey I et al. (1991) A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir. (Wien) 110:97-105.
108. Murray GD, Teasdale GM, Schmitz H. (1996) Nimodipine in traumatic subarachnoid haemorrhage: a re-analysis of the HIT I and HIT II trials. Acta Neurochir. (Wien) 138:1163-7.
109. Teasdale G et al. (1992) A randomized trial of nimodipine in severe head injury: HIT I. British/Finnish Co-operative Head Injury Trial Group. J. Neurotrauma 9 Suppl 2:S545-50.
110. Teasdale G et al. (1990) The effect of nimodipine on outcome after head injury: a prospective randomised control trial. The British/Finnish Co-operative Head Injury Trial Group. Acta Neurochir. Suppl. (Wien) 51:315-6.
111. Langham J, Goldfrad C, Teasdale G, Shaw D, Rowan K. (2003) Calcium channel blockers for acute traumatic brain injury. Cochrane Database Syst. Rev. CD000565.
112. Ray SK, Dixon CE, Banik NL. (2002) Molecular mechanisms in the pathogenesis of traumatic brain injury. Histol. Histopathol. 17:1137-52.
113. Francel PC. (1992) Bradykinin and neuronal injury. J. Neurotrauma 9 Suppl 1:S27-45.
114. Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG. (1994) Glutamate-mediated astrocyte-neuron signalling. Nature 369:744-7.
115. Ellis EF, Heizer ML, Hambrecht GS, Holt SA, Stewart JM, Vavrek RJ. (1987) Inhibition of bradykinin- and kallikrein-induced cerebral arteriolar dilation by a specific bradykinin antagonist. Stroke 18:792-5.
116. Bhoola KD, Figueroa CD, Worthy K. (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1-80.
117. Kaplanski J et al. (2002) LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J. Neurotrauma 19:953-64.
118. Pruneau D, Chorny I, Benkovitz V, Artru A, Roitblat L, Shapira Y. (1999) Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J. Neurotrauma 16:1057-65.
119. Narotam PK et al. (1998) Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir. (Wien) 140:793-802; discussion 802-3.
120. Marmarou A et al. (1999) Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma 16:431-44.
121. Pruneau D et al. (1999) Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology 43:187-94.
122. Hellal O et al. (2003) Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J. Neurotrauma. 20:841-51.
123. Marmarou A et al. (2005) A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. J. Neurotrauma 22:1444-55.
124. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. (2007) Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J. Neurotrauma 24:1119-31.
125. Stahel PF, Smith WR, Bruchis J, Rabb CH. (2008) Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury. PPAR Res. 2008:538141.
126. Hicks RR, Keeling KL, Yang MY, Smith SA, Simons AM, Kotwal GJ. (2002) Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19:705-14.
127. Gong Y, Xi GH, Keep RF, Hoff JT, Hua Y. (2005) Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. Acta Neurochir. Suppl. 95:389-92.
128. Leinhase I et al. (2006) Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp. Neurol. 199:454-64.
129. Leinhase I et al. (2007) Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J. Neuroinflammation 4:13.